Ready to run the numbers?
Calculate exact premiums, yields, and break-even for ABBV.
Why ABBV for covered calls
AbbVie is the defensive covered call pick — high dividend yield (3.5%), stable price behavior, and moderate premiums create a triple-income stream that conservative investors love.
Healthcare stocks tend to have more predictable IV patterns than tech. ABBV's diversified pharmaceutical portfolio (Skyrizi, Rinvoq, Botox) provides fundamental stability that translates to consistent premium selling.
The combination of 3.5% dividends plus 8-12% annualized call premium makes ABBV one of the highest total-yield covered call stocks in the market.
Evaluation scorecard
Using the 6-point evaluation framework:
Earnings calendar
Schedule
Late January, late April, late July, late October
Next date
April 25, 2026 (estimated)
Avg move
2-4% post-earnings
📋 Earnings tip
ABBV's earnings moves are typically smaller than tech stocks. Lower risk of selling through earnings, but still advisable to avoid it.
Suggested setups
Three approaches depending on your risk tolerance. All assume 30-45 day cycles outside of earnings.
Triple income: premium + dividends + modest appreciation. 10%+ total yield with very low assignment risk.
The sweet spot for income investors. Combined 15%+ yield from a defensive healthcare name.
Pushes total yield above 20%. Watch for ex-dividend assignment risk.
Risk factors
Lower options liquidity
ABBV has smaller options volume than mega-cap tech. Bid-ask spreads are wider — check before selling.
Drug pipeline risk
Pharmaceutical companies face binary FDA decisions. Major drug failures can gap the stock 10%+.
Humira patent cliff
The Humira biosimilar transition is ongoing. Revenue replacement from Skyrizi/Rinvoq is the key metric.
For a complete list of covered call risks, read 5 Covered Call Mistakes That Cost Beginners Money.